Solutions

RoukenBio supports innovative biotechnology companies in advancing novel therapeutics from early drug discovery to clinical development. We combine decades of academic expertise with practical industry experience in driving large molecule and advanced therapies forward.

 

Our consultative and collaborative approach allows us to tackle challenging, complex projects for a global customer base, delivering excellence across various drug modalities and therapeutic fields. We provide industry-leading pre-established methodologies, alongside novel patented platforms or a completely custom approach designed for your specific requirements.  

FAQs

As a pre-clinical immunology CRO and comprehensive solutions provider, we cover the full spectrum of discovery to pre-IND testing including:

  • Target biology validation
  • Lead selection
  • Lead optimisation and characterisation
  • Product characterisation

We have a strong foundation in biotherapeutics including biologics (e.g. antibody and protein/peptide-based molecules) and cell-based therapies. However, we are modality agnostic and can functionally characterise any immunotherapy.

In addition to enabling drug discovery of novel therapeutic candidates, we provide extensive analytical biosimilarity services for the characterisation of biosimilars.

Our specialised CRO services redefine the traditional drug discovery process, acting as an external partner; we create custom approaches and develop novel, innovative technologies, like our IndEx-2 platform, driving real innovation across the full drug discovery process.
 

Propel drug discovery breakthroughs with RoukenBio

Difficulty doesn’t deter us; it inspires us. Give us a problem, and we’ll find your solution. Our versatile specialists embrace every obstacle as an opportunity to showcase our innovative thinking and problem-solving prowess.

BOOK A MEETING
cta-image